tradingkey.logo

Check Cap Ltd

CHEK
1.610USD
0.0000.00%
Close 02/06, 16:00ETQuotes delayed by 15 min
9.42MMarket Cap
LossP/E TTM

Check Cap Ltd

1.610
0.0000.00%

More Details of Check Cap Ltd Company

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

Check Cap Ltd Info

Ticker SymbolCHEK
Company nameCheck Cap Ltd
IPO dateFeb 19, 2015
CEOOvadia (Alex)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 19
Address29 Abba Hushi Ave.
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code3009000
Phone97248303401
Websitehttps://check-cap.com/
Ticker SymbolCHEK
IPO dateFeb 19, 2015
CEOOvadia (Alex)

Company Executives of Check Cap Ltd

Name
Name/Position
Position
Shareholding
Change
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Mr. Yuval Yanai
Mr. Yuval Yanai
Independent Director
Independent Director
--
--
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
--
--
Dr. Mary Jo Gorman, M.D.
Dr. Mary Jo Gorman, M.D.
Independent Director
Independent Director
--
--
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
--
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
--
--
Mr. Joshua (Shuki) Belkar
Mr. Joshua (Shuki) Belkar
Vice President - Operations
Vice President - Operations
--
--
Mr. Israel Hershko
Mr. Israel Hershko
Vice President - Quality Assurance and Regulatory Affairs
Vice President - Quality Assurance and Regulatory Affairs
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Mr. Yuval Yanai
Mr. Yuval Yanai
Independent Director
Independent Director
--
--
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
--
--
Dr. Mary Jo Gorman, M.D.
Dr. Mary Jo Gorman, M.D.
Independent Director
Independent Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: 7 hours ago
Updated: 7 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EquityLine Alternate Assets GP Inc
10.46%
Ramanathan (Vijay)
4.94%
Symetryx Corp
4.65%
BNP Paribas Securities Corp. North America
0.30%
Dimensional Fund Advisors, L.P.
0.12%
Other
79.53%
Shareholders
Shareholders
Proportion
EquityLine Alternate Assets GP Inc
10.46%
Ramanathan (Vijay)
4.94%
Symetryx Corp
4.65%
BNP Paribas Securities Corp. North America
0.30%
Dimensional Fund Advisors, L.P.
0.12%
Other
79.53%
Shareholder Types
Shareholders
Proportion
Corporation
15.11%
Individual Investor
4.94%
Research Firm
0.41%
Investment Advisor/Hedge Fund
0.16%
Investment Advisor
0.11%
Bank and Trust
0.05%
Other
79.22%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
31
46.22K
2.97%
--
2025Q3
31
46.22K
2.97%
-83.61K
2025Q2
30
129.91K
3.13%
+25.59K
2025Q1
31
104.32K
4.46%
-156.41K
2024Q4
32
147.67K
2.55%
+134.65K
2024Q3
33
13.02K
3.40%
+4.10K
2024Q2
36
9.37K
3.50%
-1.09K
2024Q1
41
13.66K
3.76%
-206.06K
2023Q4
43
68.48K
6.43%
+25.25K
2023Q3
45
28.34K
6.39%
+11.71K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
EquityLine Alternate Assets GP Inc
762.72K
10.46%
--
--
Dec 31, 2024
Ramanathan (Vijay)
360.00K
4.94%
--
--
Dec 31, 2024
Symetryx Corp
338.63K
4.65%
--
--
Dec 31, 2024
BNP Paribas Securities Corp. North America
21.64K
0.3%
+1.50K
+7.45%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
8.96K
0.12%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
476.00
0.01%
-5.47K
-91.99%
Sep 30, 2025
Morgan Stanley & Co. LLC
6.30K
0.09%
+2.30K
+57.44%
Sep 30, 2025
National Bank of Canada
3.27K
0.04%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
2.93K
0.04%
--
--
Nov 30, 2025
J.P. Morgan Securities LLC
1.50K
0.02%
-210.00
-12.28%
Sep 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
KeyAI